Previous 10 | Next 10 |
– Preclinical data in ASD model demonstrate the differences between MM-402 (R-MDMA), S-MDMA and Racemic MDMA with enhanced pro-social effects and reduced hyperactivity – Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “Mi...
2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...
Psychedelics are projected to enjoy a compound annual growth rate (CAGR) of 55% and achieve a $7.2 billion valuation by 2029. A recent report from data and analytics firm GlobalData revealed that the psychedelic drug market is poised to experience robust growth before the end of the decade th...
2023-09-26 13:17:43 ET More on psychedelic drug development Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Qui...
New research has revealed that a single dose of psilocybin, the main psychoactive agent in psychedelic mushrooms, can boost neuroplasticity in users. Scientists found that the psychedelic was capable of inducing neural changes that were associated with reductions in depression symptoms. Neur...
2023-09-20 08:29:39 ET Palm Beach, FL – September 20, 2023 – FinancialNewsMedia.com News Commentary – The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for abuse deterre...
2023-09-19 08:00:18 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – September 19, 2023 – Depression is costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twi...
Recent research published in the “ International Journal of Mental Health and Addiction ” has indicated that psychedelic use may result in reduced cocaine intake. The study found that while psychedelic users reported either reducing or completely stopping their intake of cocaine , ...
2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMe...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...